PMID- 12515728 OWN - NLM STAT- MEDLINE DCOM- 20030618 LR - 20210206 IS - 0006-4971 (Print) IS - 0006-4971 (Linking) VI - 101 IP - 8 DP - 2003 Apr 15 TI - Prenatal and postnatal myeloid cells demonstrate stepwise progression in the pathogenesis of MLL fusion gene leukemia. PG - 3229-35 AB - The steps to leukemia following an in utero fusion of MLL (HRX, ALL-1) to a partner gene in humans are not known. Introduction of the Mll-AF9 fusion gene into embryonic stem cells results in leukemia in mice with cell-type specificity similar to humans. In this study we used myeloid colony assays, immunophenotyping, and transplantation to evaluate myelopoiesis in Mll-AF9 mice. Colony assays demonstrated that both prenatal and postnatal Mll-AF9 tissues have significantly increased numbers of CD11b(+)/CD117(+)/Gr-1(+/-) myeloid cells, often in compact clusters. The self-renewal capacity of prenatal myeloid progenitors was found to decrease following serial replating of colony-forming cells. In contrast, early postnatal myeloid progenitors increased following replating; however, the enhanced self-renewal of early postnatal myeloid progenitor cells was limited and did not result in long-term cell lines or leukemia in vivo. Unlimited replating, long-term CD11b/Gr-1(+) myeloid cell lines, and the ability to produce early leukemia in vivo in transplantation experiments, were found only in mice with overt leukemia. Prenatal Mll-AF9 tissues had reduced total (mature and progenitor) CD11b/Gr-1(+) cells compared with wild-type tissues. Colony replating, immunophenotyping, and cytochemistry suggest that any perturbation of cellular differentiation from the prenatal stage onward is partial and largely reversible. We describe a novel informative in vitro and in vivo model system that permits study of the stages in the pathogenesis of Mll fusion gene leukemia, beginning in prenatal myeloid cells, progressing to a second stage in the postnatal period and, finally, resulting in overt leukemia in adult animals. FAU - Johnson, Jennifer J AU - Johnson JJ AD - University of Minnesota Cancer Center, Minneapolis, MN 55455, USA. FAU - Chen, Weili AU - Chen W FAU - Hudson, Wendy AU - Hudson W FAU - Yao, Qing AU - Yao Q FAU - Taylor, Marnie AU - Taylor M FAU - Rabbitts, Terence H AU - Rabbitts TH FAU - Kersey, John H AU - Kersey JH LA - eng GR - CA49721/CA/NCI NIH HHS/United States GR - CA87053/CA/NCI NIH HHS/United States PT - Comparative Study PT - Journal Article PT - Research Support, Non-U.S. Gov't PT - Research Support, U.S. Gov't, P.H.S. DEP - 20021219 PL - United States TA - Blood JT - Blood JID - 7603509 RN - 0 (MLL-AF9 fusion protein, human) RN - 0 (Oncogene Proteins, Fusion) RN - 149025-06-9 (Myeloid-Lymphoid Leukemia Protein) SB - IM MH - Age Factors MH - Animals MH - Bone Marrow/embryology/growth & development MH - Bone Marrow Transplantation MH - Cell Transformation, Neoplastic/*genetics MH - Cellular Senescence MH - Colony-Forming Units Assay MH - Disease Progression MH - Embryo, Mammalian/cytology MH - Exons/genetics MH - Female MH - Gene Targeting MH - Gestational Age MH - Hematopoietic System/embryology/growth & development MH - Humans MH - Immunophenotyping MH - Leukemia, Experimental/etiology/genetics/*pathology MH - Liver/embryology/growth & development MH - Male MH - Mice MH - Models, Biological MH - Mutagenesis, Insertional MH - Myeloid Cells/*pathology MH - Myeloid-Lymphoid Leukemia Protein MH - Oncogene Proteins, Fusion/genetics/*physiology MH - Organ Specificity MH - Radiation Chimera MH - Stem Cells/cytology EDAT- 2003/01/08 04:00 MHDA- 2003/06/19 05:00 CRDT- 2003/01/08 04:00 PHST- 2003/01/08 04:00 [pubmed] PHST- 2003/06/19 05:00 [medline] PHST- 2003/01/08 04:00 [entrez] AID - S0006-4971(20)50825-2 [pii] AID - 10.1182/blood-2002-05-1515 [doi] PST - ppublish SO - Blood. 2003 Apr 15;101(8):3229-35. doi: 10.1182/blood-2002-05-1515. Epub 2002 Dec 19.